UK-based ProBiotix Health, a UK-based life sciences company specialising in probiotic solutions for cardiometabolic health, has signed an exclusive supply agreement with Kemin China Technology Co Ltd (Kemin China).
The deal grants Kemin China the rights to sell ProBiotix’s proprietary probiotic strain, LPLDL®, as a cardiometabolic health supplement ingredient in China, Hong Kong, and Macau, with potential expansion into other regions. Under the agreement, ProBiotix will supply LPLDL® in bulk, and Kemin China will market it under a co-branding arrangement.
China has 330 million people suffering from cardiovascular diseases, and the country’s probiotic supplement market, valued at US$2.3 billion in 2024 is projected to grow rapidly to reach US$3.6 billion by 2028.
Kemin China is a subsidiary of Kemin Industries, a US-based global ingredient supplier with more than US$1 billion in revenue and over 500 patents. The partnership is expected to expand ProBiotix’s presence in the Chinese market.
